Table of Contents

Over the past decade, medications that mimic a hormone called glucagon-like peptide-1 (GLP-1) have changed the way clinicians help patients manage weight. These drugs slow stomach emptying, help people feel full sooner and for longer, and increase insulin release in response to meals. Until recently, most GLP-1 treatments had to be injected, but now, three oral GLP-1 drugs are gaining attention.

Foundayo (orforglipron) is a newly approved small-molecule GLP-1 receptor agonist for weight management. Rybelsus, the tablet form of semaglutide approved for type 2 diabetes. Wegovy pill, the higher-dose semaglutide tablet approved in late 2025 for chronic weight management.

This article explains how they work for weight loss, shows evidence from clinical trials, and compares their benefits, side effects, and practical considerations.

Key Takeaways

  • All three drugs activate the GLP-1 receptor, but orforglipron is a small molecule with higher oral bioavailability than semaglutide. Semaglutide pills rely on an absorption enhancer and strict fasting for adequate absorption.
  • Foundayo and Wegovy pills produce double-digit percentage weight loss in clinical trials, whereas Rybelsus yields modest reductions.
  • Foundayo may be taken without regard to meals, while Rybelsus and Wegovy tablets must be swallowed on an empty stomach with a sip of water and require a 30-minute wait before eating.
  • Nausea, vomiting, and diarrhea occur across all three drugs. These symptoms typically lessen over time but may lead to discontinuation in some patients.
  • Wegovy pill is expensive, and insurance coverage for weight-loss medications is variable. Rybelsus may be covered for diabetes but not for weight management. Self-pay pricing of Foundayo starts at $149 per month for the lowest dose through the LillyDirect program, but most patients are expected to pay around $349 per month.

How Foundayo, Rybelsus, and Wegovy pills work for weight loss

After absorption, all of them activate GLP-1 receptors and produce similar effects:

    • increase insulin release when glucose is high
    • suppress glucagon
    • slow gastric emptying
    • reduce appetite and food intake

The main difference is how each drug gets through the stomach and into the bloodstream.

Rybelsus is the brand name for oral semaglutide, available in 3 mg, 7 mg, and 14 mg tablets. To allow semaglutide to survive stomach acid, Rybelsus tablets contain an absorption enhancer called SNAC.

SNAC temporarily raises stomach pH and protects the Rybelsus tablet so it can cross the stomach lining. Because of this, Rybelsus must be taken on an empty stomach with a small amount of water and no food or other medication for at least 30 minutes.

The Wegovy pill is also an oral formulation of semaglutide, but at a higher dose (25 mg), developed specifically for chronic weight management. Like Rybelsus, the Wegovy pill uses SNAC to protect semaglutide from stomach acid.

Foundayo (orforglipron) is a non-peptide oral GLP-1 receptor agonist. Unlike Rybelsus and Wegovy pill which are peptide-based drugs, orforglipron is a small molecule.

It targets the same GLP-1 receptor and triggers similar signals. But because it is not a peptide, orforglipron does not require the absorption enhancer used in Rybelsus and Wegovy tablets. It has an oral bioavailability of 20-40%, which is much higher than the 0.4-1% bioavailability of oral semaglutide. That means a larger portion of the drug enters the bloodstream after swallowing.

Comparing Foundayo, Rybelsus, and Wegovy Pill for weight loss

The Wegovy pill has shown the largest weight reductions in trials, reaching about 14% at 64 weeks with the 25 mg dose. Foundayo followed with 12.4% weight loss in ATTAIN-1, while Rybelsus produced 2-5% weight loss in PIONEER trials.

The table below summarizes weight-loss outcomes reported in major trials for these three oral GLP-1 agents. These numbers come from controlled studies and may not reflect real-world results. Individual responses can vary widely.

Medication Doses Population Average Weight Loss Notes
Foundayo 0.8-17.2 mg (daily) Adults with obesity or type 2 diabetes Up to 27 lbs of weight loss at 72 weeks FDA-approved for weight loss
Rybelsus 3-14 mg (daily) Adults with type 2 diabetes Up to 10 lbs of weight loss at 52 weeks Not FDA-approved for weight loss. Using Rybelsus for weight loss is considered off-label.
Wegovy pill 1.5-25 mg (daily) Adults with obesity or overweight without diabetes Up to 33 lbs of weight loss at 64 weeks FDA-approved for weight loss

Foundayo weight loss outcomes

Eli Lilly’s ATTAIN program evaluated orforglipron in both non-diabetic obesity (ATTAIN-1) and type 2 diabetes (ATTAIN-2) populations.

In ATTAIN-1, the highest dose (36 mg) produced a 12.4% reduction in body weight at 72 weeks, corresponding to about 27.3 lbs. Even the 12 mg dose led to a 9.3% loss (about 20.7 lbs). Nearly 60% of participants taking 36 mg achieved at least a 10% reduction in body weight, and nearly 40% achieved a 15% or greater reduction.

In ATTAIN-2, the reductions were slightly smaller than in the non-diabetic population. Weight loss averaged 5-10% after 72 weeks in people with diabetes.

Rybelsus weight loss outcomes

The efficacy of Rybelsus has been studied extensively in the PIONEER program. While Rybelsus is not approved for weight loss, many people do lose modest weight while taking it for diabetes. The 14 mg dose delivers the most weight loss.

Here’s a summary of the weight loss results of Rybelsus 14 mg from PIONEER trials:

Trial

 Weight Loss (kg)

Weight Loss (lbs)
PIONEER-1

2.3 kg

5.1 lbs
PIONEER-2

4.7 kg

10.4 lbs
PIONEER-3

2.5 kg

5.51 lbs
PIONEER-4

4.4 kg

9.7 lbs
PIONEER-5

3.7 kg

8.1 lbs
PIONEER-6

4.2 kg

9.3 lbs
PIONEER-7

2.6 kg

5.7 lbs
PIONEER-8

3.3 kg

7.3 lbs

In a 6-month study of 1,864 adults with type 2 diabetes, people weighing around 200 lb who took Rybelsus 7 mg lost 4.8 lb on average, and those taking 14 mg lost 6.8 lb.

When used in a real-world setting, researchers followed 93 adults without diabetes who used Rybelsus 14 mg for one year to treat obesity. The average weight reduction among completers was 5.7% of body weight (about 5.9 kg or 13 lbs). Waist circumference decreased by 5.5 cm, and body mass index fell by 2 kg/m². Clinically significant weight loss (at least 5%) was achieved in 48% of participants, but very few (4%) lost 15% or more.

Foundayo vs. Rybelsus

The ACHIEVE-3 trial compared orforglipron with Rybelsus in adults with type 2 diabetes. At 52 weeks, participants taking orforglipron 36 mg lost 19.7 lbs (9.2% of body weight) versus 11 lbs (5.3%) for those taking Rybelsus 14 mg.

Wegovy pill weight loss outcomes

The OASIS program evaluated high-dose oral semaglutide for weight loss in people with obesity or overweight without diabetes.

In OASIS-4, adults taking the 25 mg Wegovy pill lost an average of 14% of their body weight (about 33 lb from a baseline of 235 lb). Approximately 76% of participants on the pill lost at least 5% of their starting weight, about 60% lost 10% or more, 47% lost at least 15%, and 28% lost at least 20%.

Convenience, dosing, and adherence

Woman taking medication tablet with glass of water

Foundayo is likely the easiest to incorporate into a daily routine because it does not require fasting or strict timing relative to meals. It’s taken orally once daily, with or without food, and tablets should be swallowed whole without breaking, crushing, or chewing. Treatment starts at 0.8 mg once daily, increasing to 2.5 mg after at least 30 days, then to 5.5 mg after another 30 days. Based on response and tolerability, the dose may be further increased stepwise every 30 days to 9 mg, 14.5 mg, or up to a maximum of 17.2 mg once daily.

Rybelsus and Wegovy pills must both be taken first thing in the morning with no food or other medications for at least 30 minutes. This can be inconvenient for people who need morning coffee or who take other medicines. Forgetting about the timing may reduce absorption and lead to lower efficacy.

The Wegovy pill also requires a step-up dosing schedule that spans several months, starting at 1.5 mg and increasing to 25 mg. You may have to delay dose increases if you experience side effects. To compare, Rybelsus reaches its maintenance dose (14 mg) within two months.

Side effects and tolerability differences

Gastrointestinal issues are common across all GLP-1 drugs. Nausea, vomiting, diarrhea, and constipation occur most frequently during dose increases.

The Wegovy pill has high rates of gastrointestinal side effects. About 74% of participants experienced at least one GI symptom, compared with 42% in the placebo group. Discontinuation due to adverse events was similar between the Wegovy and placebo groups (7% vs. 6%).

In Rybelsus trials,

    • constipation occurred in up to 23% of patients,
    • diarrhea occurred in up to 22%, and
    • nausea occurred in up to 19%.

Only a minority stopped Rybelsus because of side effects. Less than 10% of patients stopped the 7 mg dose, and less than 17% stopped the 14 mg dose.

The side effects of orforglipron resemble those of other GLP-1 drugs. A 2024 meta-analysis suggests orforglipron may have the highest nausea risk among oral GLP-1 drugs, possibly because the drug is absorbed quickly. Around 7.8% of patients stopped treatment due to side effects, compared with 2.7% on placebo.

If you’re considering any of these medications, discuss your personal risk factors with a doctor.

Cost, insurance coverage, and accessibility

Among the three oral GLP-1 drugs, Foundayo and Wegovy tablets currently have the lowest price in the US.

The list price of Rybelsus is about $997.58 per month for a 30-day supply (all doses). And as a diabetes medication, Rybelsus may be covered by insurance for people with type 2 diabetes. For those using it off-label for weight loss, coverage is unlikely. Out-of-pocket prices vary widely, but discount programs may reduce costs.

Self-pay pricing for the Wegovy pill starts at $149 per month for the 1.5 mg and 4 mg doses through August 31, 2026. Afterward, the 4 mg dose increases to $199 per month, while the 9 mg and 25 mg doses are priced at $299 per month.

Similarly, self-pay pricing for Foundayo starts at $149 per month for the lowest dose through the LillyDirect program, but most patients are expected to pay about $349 per month. Refill incentives can potentially reduce the cost to as low as $299.

Buy Rybelsus from Canada

Starting from $298

Ready to Buy Rybelsus Online?

Choose BuyCanadianInsulin.com for affordable medications such as Rybelsus and take control of your health with reliable, cost-effective options today!

SAVE 10% with coupon code:

Which oral GLP-1 drug should you choose?

The best choice depends on what matters most to you. Here’s a quick look at the pros and cons of each medication.

Pros and cons of Foundayo

Advantages:

  • Strong weight loss: In phase 3 trials, orforglipron produced weight loss results comparable to some injectable GLP-1 drugs and greater than Rybelsus.
  • Convenience: It can be taken without strict fasting rules, making it easier to fit into any routine.
  • Stable exposure: Its higher oral bioavailability leads to more consistent drug levels in the body.
  • Potential cost advantages: Being a small molecule may reduce manufacturing costs and improve access.

Disadvantages:

  • Gastrointestinal side effects: Studies suggest orforglipron may have the highest nausea risk among oral GLP-1 drugs.
  • Long-term safety data: Although trials up to 72 weeks show good results, there are limited data on rare side effects or very long-term outcomes.
  • Limited insurance coverage: Insurance coverage is still limited, partly because it was only recently launched.

Pros and cons of Rybelsus

Advantages:

  • Modest weight loss: Rybelsus leads to weight reductions of roughly 5-10 lbs in many clinical trials.
  • Improved blood sugar: In diabetic patients, Rybelsus effectively lowers HbA1c and fasting glucose.
  • Availability: Rybelsus is already widely available.

Disadvantages:

  • Strict administration guidelines: The pill must be taken first thing in the morning with no more than 4 oz of water and no food, drinks, or other medications for 30 minutes. This may be challenging for people with busy routines.
  • Limited weight loss: Average weight reductions are modest compared to other oral GLP-1 options.

Pros and cons of the Wegovy pill

Advantages:

  • Significant weight loss: Participants in trials lost an average of 14% of their body weight, and nearly one-third achieved at least 20% loss.
  • Daily pill alternative to injections: Provides an option for people who hesitate to use injectable medications for weight loss.
  • Comparable efficacy to injections: The 25 mg pill produced weight loss similar to the 2.4 mg injection.
  • Improved quality of life: Participants reported better physical function and improvements in cardiometabolic markers.

Disadvantages:

  • Strict dosing guidelines: Like Rybelsus, the pill must be taken on an empty stomach with water only, and there is a 30-minute waiting period before eating, drinking, or taking other medications.
  • Dose escalation period: It takes several months to reach the maintenance dose, and side effects may be more pronounced during each increase.
  • Limited insurance coverage: Insurance coverage is still limited, partly because it was only recently launched.

Bottom line

Oral GLP-1 medications are creating new options for treating obesity and type 2 diabetes. Foundayo is a newer small-molecule GLP-1 drug that has shown strong weight-loss results and may offer simpler dosing. Rybelsus provides semaglutide in a daily pill but typically leads to more modest weight loss and must be taken on an empty stomach. The Wegovy pill delivers a higher dose of semaglutide and can produce weight loss similar to injections, but it requires careful dosing and titration.

As research continues, more oral GLP-1 drugs may become available, and future studies will help clarify how these medications compare in different patients.

Frequently Asked Questions

No. Rybelsus and Wegovy both contain semaglutide, but they are approved for different uses and use different doses. Rybelsus is mainly prescribed for type 2 diabetes, while Wegovy is approved specifically for chronic weight management.

No. Orforglipron is a small-molecule GLP-1 receptor agonist, while Rybelsus contains the peptide drug semaglutide. They activate the same GLP-1 pathway but are chemically different medications.

There is no pill proven to consistently outperform Wegovy in clinical trials.

Among prescription pills, the Wegovy pill has produced some of the largest weight reductions in studies. Drugs targeting the same GLP-1 pathway, such as Rybelsus or Foundayo, can also help reduce appetite and body weight. But injectable medications like Wegovy or Zepbound still tend to achieve greater average weight loss.

Research suggests the oral form of Wegovy can produce comparable weight loss to its injectable version.

Many people lose fat from several parts of the body, including the abdomen, when taking Wegovy. However, the medication does not target belly fat specifically. Weight loss occurs throughout the body as overall fat mass decreases.

Both versions use the same active drug but differ in dosing and delivery. Injectable Wegovy currently has more clinical data supporting its effectiveness. The pill may appeal to people who prefer oral medication over injections.

Most people begin to notice appetite changes and gradual weight loss within the first few weeks of treatment. With Wegovy pills, meaningful weight loss typically develops over several months as the dose is slowly increased. Maximum results in trials are usually measured after about a year or more.

The Wegovy pill and injection have similar low costs for insured patients, which is around $25 per month, but differ significantly for self-pay. The pill starts at $149 per month for lower doses (1.5 mg and 4 mg) and $299 for higher doses (9 mg and 25 mg). In contrast, the Wegovy injection has a much higher list price of $1,349.02 per package, though cash-pay programs reduce this to about $349 per month across doses ranging from 0.25 mg to 2.4 mg.

Weight regain can occur after stopping Wegovy because appetite may return. Studies show that a year after stopping weekly semaglutide 2.4 mg along with lifestyle intervention, participants regained nearly two-thirds of their previous weight loss.

Articles you may also be interested in

Sources

Alper, A., Peleg, G., et.al. (2026). Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review. Cardiovascular Diabetology – Endocrinology Reports, 12(1), 9. https://doi.org/10.1186/s40842-025-00270-4

Horn, D. B., Ryan, D. H., et.al. (2025). Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. The Lancet, 406(10522), 2927–2944. https://doi.org/10.1016/s0140-6736(25)02165-8

Lilly’s oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine | Eli Lilly and Company. (n.d.). Eli Lilly and Company. https://lilly.gcs-web.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-meaningful-weight

Aroda, V. R., Rosenstock, J., et.al. (2019). PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care, 42(9), 1724–1732. https://doi.org/10.2337/dc19-0749

Rodbard, H. W., Rosenstock, J., et.al. (2019). Oral semaglutide versus empagliflozin in patients with Type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care, 42(12), 2272–2281. https://doi.org/10.2337/dc19-0883

Rosenstock, J., Allison, D., et.al. (2019). Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea. JAMA, 321(15), 1466. https://doi.org/10.1001/jama.2019.2942

Pratley, R., Amod, A., et.al. (2019). Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. The Lancet, 394(10192), 39–50. https://doi.org/10.1016/s0140-6736(19)31271-1

Mosenzon, O., Blicher, T. M., et.al. (2019). Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. The Lancet Diabetes & Endocrinology, 7(7), 515–527. https://doi.org/10.1016/s2213-8587(19)30192-5

Zinman, B., Aroda, V. R., et.al. (2019). Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with Type 2 diabetes: the PIONEER 8 trial. Diabetes Care, 42(12), 2262–2271. https://doi.org/10.2337/dc19-0898

Krajnc, M., Kuhar, N., & Koceva, A. (2025). Oral semaglutide for the treatment of obesity: a retrospective real-world study. Frontiers in Endocrinology, 16, 1593334. https://doi.org/10.3389/fendo.2025.1593334

Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet | Eli Lilly and Company. (n.d.). Eli Lilly and Company. https://lilly.gcs-web.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-delivered-superior-blood-sugar

RYBELSUS® vs Other Diabetes Pills | RYBELSUS® (semaglutide) tablets. (n.d.). https://www.rybelsus.com/why-rybelsus/rybelsus-vs-other-diabetes-pills.html

Wegovy Pill Trial Findings for Weight Loss | Wegovy® (semaglutide). (n.d.). https://www.wegovy.com/obesity/is-wegovy-right-for-me/wegovy-pill-results.html

Wharton, S., Lingvay, I., et.al. (2025). Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine, 393(11), 1077–1087. https://doi.org/10.1056/nejmoa2500969

Pieber, T. R., Bode, B., et.al. (2019). Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. The Lancet Diabetes & Endocrinology, 7(7), 528–539. https://doi.org/10.1016/s2213-8587(19)30194-9

Husain, M., Birkenfeld, A. L., et.al. (2019). Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 381(9), 841–851. https://doi.org/10.1056/nejmoa1901118

Araki, E., Terauchi, Y., et.al. (2021). Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials. Diabetes Obesity and Metabolism, 23(12), 2785–2794. https://doi.org/10.1111/dom.14536

Yao, H., Zhang, A., et.al. (2024). Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ, 384, e076410. https://doi.org/10.1136/bmj-2023-076410

Kansakar, U., Jankauskas, S. S., et.al. (2026). Orforglipron: A comprehensive review of an oral Small-Molecule GLP-1 receptor agonist for obesity and Type 2 diabetes. International Journal of Molecular Sciences, 27(3), 1409. https://doi.org/10.3390/ijms27031409

Wegovy® (semaglutide) tablet 25 mg, injection 2.4 mg Cost, Coverage, & Savings Resources | NovoCare®. (n.d.). https://www.novocare.com/patient/medicines/wegovy.html

RYBELSUS® (semaglutide) tablets 7 mg or 14 mg List Price & Insurance Coverage Explained | NovoCare®. (n.d.). https://www.novocare.com/diabetes/products/rybelsus/explaining-list-price.html